• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Oculis Holding AG

    3/27/26 6:30:08 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Oculis Holding AG

    (Name of Issuer)


    Ordinary Shares, CHF 0.01 par value per share

    (Title of Class of Securities)




    H5870P102

    (CUSIP Number)
    02/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    H5870P102


    1Names of Reporting Persons

    BVCF IV, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,436,902.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,436,902.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,436,902.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.14 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026.


    SCHEDULE 13G

    CUSIP Number(s):
    H5870P102


    1Names of Reporting Persons

    BEYEOTECH
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,436,902.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,436,902.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,436,902.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.14 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026.


    SCHEDULE 13G

    CUSIP Number(s):
    H5870P102


    1Names of Reporting Persons

    BVCF IV GP, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,436,902.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,436,902.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,436,902.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.14 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026.


    SCHEDULE 13G

    CUSIP Number(s):
    H5870P102


    1Names of Reporting Persons

    Zhi Yang
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CHINA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,436,902.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,436,902.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,436,902.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.14 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Oculis Holding AG
    (b)Address of issuer's principal executive offices:

    Bahnhofstrasse 20 Zug, V8, CH-6300
    Item 2. 
    (a)Name of person filing:

    This statement is filed by (i) BVCF IV, L.P. ("Fund"), a limited partnership incorporated under the laws of the Cayman Islands, (ii) BEYEOTECH ("Beyeotech"), a company organized and existing under the laws of the Cayman Islands, (iii) BVCF IV GP, Ltd. ("GP"), a limited company incorporated under the laws of the Cayman Islands, and (iv) Mr. Zhi Yang, a director and sole shareholder of GP (Fund, Beyeotech, GP and Mr. Zhi Yang are collectively referred to as the "Reporting Persons"). Beyeotech directly holds the 2,436,902 Ordinary Shares being reported in this statement. Beyeotech is a wholly-owned subsidiary of Fund, GP is the general partner of Fund and Mr. Zhi Yang is the sole shareholder and director of GP. GP, by virtue of it being the general partner of Fund, may be deemed to have voting control and investment discretion over the securities held by Beyeotech. Mr. Zhi Yang, by virtue of being the director and sole shareholder of GP, may be deemed to have voting control and investment discretion over the securities held by Beyeotech. Each of the Reporting Persons has entered into a Joint Filing Agreement, dated April 28, 2023, pursuant to which such Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Beyeotech is 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands. The address of the principal business office of each of Fund, GP and Mr. Zhi Yang is 763 Mengzi Road, Suite 2604, Shanghai, China 200023.
    (c)Citizenship:

    See Row 4 of each cover page.
    (d)Title of class of securities:

    Ordinary Shares, CHF 0.01 par value per share
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of each cover page.
    (b)Percent of class:

    See Row 11 of each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of each cover page.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of each cover page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BVCF IV, L.P.
     
    Signature:By: BVCF IV GP, Ltd., its general partner /s/ Zhi Yang
    Name/Title:Zhi Yang/Director
    Date:03/27/2026
     
    BEYEOTECH
     
    Signature:/s/ Bernard Yang Feng
    Name/Title:Bernard Yang Feng/Director
    Date:03/27/2026
     
    BVCF IV GP, Ltd.
     
    Signature:/s/ Zhi Yang
    Name/Title:Zhi Yang/Director
    Date:03/27/2026
     
    Zhi Yang
     
    Signature:/s/ Zhi Yang
    Name/Title:Zhi Yang
    Date:03/27/2026
    Exhibit Information

    Joint Filing Agreement dated April 28, 2023 https://www.sec.gov/Archives/edgar/data/1761158/000119312523131200/d499516dex991.htm

    Get the next $OCS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCS

    DatePrice TargetRatingAnalyst
    12/19/2025$38.00Overweight
    Analyst
    8/27/2025$36.00Buy
    Needham
    12/5/2023$30.00Buy
    Chardan Capital Markets
    10/5/2023$35.00Buy
    Stifel
    6/14/2023$22.00Buy
    BofA Securities
    6/12/2023$28.00Buy
    H.C. Wainwright
    6/8/2023$58.00Outperform
    Robert W. Baird
    5/10/2023$23.00Buy
    Pareto
    More analyst ratings

    $OCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Oculis Holding AG with a new price target

    Analyst initiated coverage of Oculis Holding AG with a rating of Overweight and set a new price target of $38.00

    12/19/25 8:50:10 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on Oculis Holding AG with a new price target

    Needham initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $36.00

    8/27/25 8:25:52 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Oculis Holding AG with a new price target

    Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

    12/5/23 8:03:01 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Oculis Holding AG

    SCHEDULE 13G/A - Oculis Holding AG (0001953530) (Subject)

    3/27/26 6:30:08 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Oculis Holding AG

    6-K - Oculis Holding AG (0001953530) (Filer)

    3/4/26 4:31:29 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-3ASR filed by Oculis Holding AG

    F-3ASR - Oculis Holding AG (0001953530) (Filer)

    3/4/26 4:19:03 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

    ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (NASDAQ:OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting. This premier annual gathering of neuro-ophthalmology experts worldwide provides a scientific forefront platform for presenting transformative clinical data amongst leading clinicians, researchers, and thought leaders. As a Platinum Sponsor of the 2026 Congress, Oculis is proud to support the most influential

    3/16/26 5:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis to Participate in Upcoming Investor Conferences

    ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis' management will participate in upcoming investor conferences in March. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: Privosegtor (PIONEER program) granted breakthrough therapy designation for optic neuritis (ON

    3/5/26 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

    Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market opportunity of over $7 billion Cash, cash equivalents, and short-term investments of $268.7 million as of December 31, 2025, providing cash runway into 2029 ZUG, Switzerland, March 3, 2026 -- Oculis Holding AG (NASDAQ:OCS) (Oculis), a global biopharmace

    3/3/26 4:05:00 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Leadership Updates

    Live Leadership Updates

    View All

    Oculis Appoints Katie Kazem as Chief Legal Officer

    Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones ZUG, Switzerland, February 17, 2026 -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced the appointment of Katie Kazem as Chief Legal Officer, leading Oculis' le

    2/17/26 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

    Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySebastian Wolf, M.D., Ph.D. appointed as Chief Medical Advisor, Ophthalmology, following the material advancement in retina programs with recent enrollment completion of Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema and positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company f

    8/25/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Publishes Invitation to the Annual General Meeting

    ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

    5/9/25 4:05:00 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Financials

    Live finance-specific insights

    View All

    Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

    Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today announces the advancement of Privosegtor into a registrational program for neuro-ophtha

    10/6/25 4:07:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

    DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event

    5/22/23 6:30:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

    ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica

    4/4/23 7:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Oculis Holding AG

    SC 13G - Oculis Holding AG (0001953530) (Subject)

    12/9/24 9:43:55 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oculis Holding AG

    SC 13G/A - Oculis Holding AG (0001953530) (Subject)

    11/7/24 4:15:49 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care